We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets a... Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer. Show more
Julie Eastland appointed Chief Executive Officer, President and Director Ingmar Bruns, M.D., appointed Chief Medical Officer Scott Myers appointed to the Board of Directors as Chairperson SAN...
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small...
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm PR Newswire NEW YORK, Sept. 16, 2024 NEW YORK, Sept. 16, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder...
SAN DIEGO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated...
SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated...
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.44 | 13.880126183 | 3.17 | 3.7 | 3.08 | 772783 | 3.4193319 | CS |
4 | 0.87 | 31.7518248175 | 2.74 | 4.44 | 2.71 | 1403246 | 3.57767827 | CS |
12 | 0.38 | 11.7647058824 | 3.23 | 5.44 | 2.6612 | 2082610 | 3.56009983 | CS |
26 | -7.89 | -68.6086956522 | 11.5 | 13 | 2.6612 | 1720580 | 4.08303576 | CS |
52 | -6.98 | -65.9112370161 | 10.59 | 18.07 | 2.6612 | 1264580 | 7.00418523 | CS |
156 | -73.39 | -95.3116883117 | 77 | 85.95 | 2.6612 | 873524 | 16.83393055 | CS |
260 | -21.08 | -85.3786958283 | 24.69 | 87.19 | 2.6612 | 653419 | 21.55557056 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions